Alphabet, UnitedHealth Group, Hims & Hers Health, Oracle, and Amgen are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies operating in the healthcare sector, including pharmaceutical manufacturers, biotechnology firms, medical device makers, hospitals and health insurers. By owning these equities, investors gain exposure to businesses that research, develop and deliver medical treatments, equipment and services. Healthcare stocks often exhibit defensive characteristics—driven by steady demand for medical care—but can be sensitive to regulatory changes, patent expirations and breakthroughs in medical technology. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Alphabet (GOOGL)
Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube.
Shares of GOOGL traded up $1.42 during mid-day trading on Wednesday, hitting $196.09. The company's stock had a trading volume of 11,589,825 shares, compared to its average volume of 36,920,703. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.90 and a quick ratio of 1.90. The firm has a 50-day moving average price of $179.29 and a 200 day moving average price of $172.97. Alphabet has a fifty-two week low of $140.53 and a fifty-two week high of $207.05. The stock has a market capitalization of $2.37 trillion, a price-to-earnings ratio of 20.87, a PEG ratio of 1.32 and a beta of 1.01.
Read Our Latest Research Report on GOOGL
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Shares of UnitedHealth Group stock traded down $3.31 on Wednesday, reaching $247.69. 8,477,831 shares of the company were exchanged, compared to its average volume of 12,090,611. The stock has a fifty day moving average price of $294.89 and a 200-day moving average price of $411.68. The firm has a market capitalization of $224.69 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 1.55 and a beta of 0.43. UnitedHealth Group has a fifty-two week low of $234.60 and a fifty-two week high of $630.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.73.
Read Our Latest Research Report on UNH
Hims & Hers Health (HIMS)
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
NYSE HIMS traded down $4.83 on Wednesday, hitting $50.69. 27,413,827 shares of the stock were exchanged, compared to its average volume of 34,313,508. Hims & Hers Health has a 52-week low of $13.47 and a 52-week high of $72.98. The company has a market capitalization of $11.35 billion, a price-to-earnings ratio of 63.49, a P/E/G ratio of 2.34 and a beta of 2.08. The company's 50-day moving average price is $53.83 and its two-hundred day moving average price is $44.59.
Read Our Latest Research Report on HIMS
Oracle (ORCL)
Oracle Corporation offers products and services that address enterprise information technology environments worldwide. Its Oracle cloud software as a service offering include various cloud software applications, including Oracle Fusion cloud enterprise resource planning (ERP), Oracle Fusion cloud enterprise performance management, Oracle Fusion cloud supply chain and manufacturing management, Oracle Fusion cloud human capital management, Oracle Cerner healthcare, Oracle Advertising, and NetSuite applications suite, as well as Oracle Fusion Sales, Service, and Marketing.
ORCL traded down $1.65 on Wednesday, reaching $254.02. 4,511,811 shares of the company traded hands, compared to its average volume of 12,033,127. The stock's 50 day moving average price is $217.36 and its 200-day moving average price is $176.15. The company has a debt-to-equity ratio of 4.07, a current ratio of 0.75 and a quick ratio of 0.75. Oracle has a 52-week low of $118.86 and a 52-week high of $260.87. The company has a market cap of $713.50 billion, a price-to-earnings ratio of 58.50, a PEG ratio of 3.77 and a beta of 1.43.
Read Our Latest Research Report on ORCL
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Shares of Amgen stock traded down $15.75 during trading on Wednesday, hitting $284.33. 2,411,056 shares of the stock traded hands, compared to its average volume of 2,900,181. The stock has a market cap of $152.89 billion, a P/E ratio of 25.96, a PEG ratio of 2.61 and a beta of 0.49. The company has a fifty day moving average price of $293.06 and a two-hundred day moving average price of $292.45. Amgen has a twelve month low of $253.30 and a twelve month high of $339.17. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17.
Read Our Latest Research Report on AMGN
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alphabet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphabet wasn't on the list.
While Alphabet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
